Document is current
Any future updates will be listed below
-
Authors
Dohlman, Anders B. https://orcid.org/0000-0003-3473-2878
Pan, Xiangyu https://orcid.org/0000-0002-2537-6616
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
Iliev, Iliyan D. https://orcid.org/0000-0003-0884-9749
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01CA286920, R01DK113136, R01DK121977, R01 AI178683 and R01AI163007)
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 28 July 2025
First Online: 9 September 2025
Competing interests
: A.B.D. and I.D.I. are inventors on US patent application no. PCT/US2023/029634, submitted by Cornell University and Duke University, related to the use of fungi for classifying and treating gastrointestinal and lung tumours. L.Z. is founder of a Biotech. Cie involved in the cancer/microbiome space everImmune; is president of the everImmune scientific advisory board (SAB); has obtained research funding with Pileje, Biomérieux, everImmune and Daiichi Sankyo; is a SAB member of the DKFZ and German Cancer Aid; has received honoraria from everImmune; is an employee of Gustave Roussy and the Faculté de Medecine Paris XI; is ex editor in chief of OncoImmunology; is an ex member of the SAB of EpiVax, Lytix Biopharma and Tusk Therapeutics; has past research contracts with Kaleido, Elior, Carrefour, Merus, Roche, Tusk, Pileje, Incyte, BMS, GSK, Lytix Biopharma, Innate Pharma and Transgene; is an ex member of the board of directors of Transgene; is an ex member of the SAB of Hookipa; had a teaching contract with Pierre Fabre in 2023; and is ex president of the SAB of IHU Méditerranée Infections. I.D.I. has received honoraria from Moderna. X.P. declares no competing interests.
